Alle verbonden artikelen

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.

Auteurs : Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Müller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L
Jaar : 2013
Journal : Breast Cancer Res
Volume : 15(5)
Pagina's : R86

Breast cancer and melanoma cell line identification by FTIR imaging after formalin-fixation and paraffin-embedding.

Auteurs : Verdonck M, Wald N, Janssis J, Yan P, Meyer C, Legat A, Speiser DE, Desmedt C, Larsimont D, Sotiriou C, Goormaghtigh E
Jaar : 2013
Journal : Analyst
Volume : 138(14)
Pagina's : 4083-91

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.

Auteurs : Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart-Gebhart M
Jaar : 2013
Journal : Eur. J. Cancer
Volume : 49(12)
Pagina's : 2621-32

Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial.

Auteurs : Demeestere I, Brice P, Peccatori FA, Kentos A, Gaillard I, Zachee P, Casasnovas RO, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y
Jaar : 2013
Journal : J. Clin. Oncol.
Volume : 31(7)
Pagina's : 903-9

How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer.

Auteurs : Pinto AC, de Azambuja E, Piccart-Gebhart M
Jaar : 2013
Journal : Breast Care (Basel)
Volume : 8(4)
Pagina's : 264-269

Asthma control measurement using five different questionnaires: A prospective study.

Auteurs : Vermeulen F, de Meulder I, Paesmans M, Muylle I, Bruyneel M, Ninane V
Jaar : 2013
Journal : Respir Med
Volume : 107(9)
Pagina's : 1314-21

Evaluation of the effect of computer-aided classification of benign and malignant lesions on reader performance in automated three-dimensional breast ultrasound.

Auteurs : Tan T, Platel B, Twellmann T, van Schie G, Mus R, Grivegnée A, Mann RM, Karssemeijer N
Jaar : 2013
Journal : Acad Radiol
Volume : 20(11)
Pagina's : 1381-8

Planning cancer control in Latin America and the Caribbean.

Auteurs : Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, Louis JS, Villarreal-Garza C, Unger-Saldaña K, Ferreyra M, Debiasi M, Liedke PE, Touya D, Werutsky G, Higgins M, Fan L, Vasconcelos C, Cazap E, Vallejos C, Mohar A, Knaul F, Arreola H, Batura R, Luciani S, Sullivan R, Finkelstein D, Simon S, Barrios C, Kightlinger R, Gelrud A, Bychkovsky V, Lopes G, Stefani S, Blaya M, Souza FH, Santos FS, Kaemmerer A, de Azambuja E, Zorilla AF, Murillo R, Jeronimo J, Tsu V, Carvalho A, Gil CF, Sternberg C, Dueñas-Gonzalez A, Sgroi D, Cuello M, Fresco R, Reis RM, Masera G, Gabús R, Ribeiro R, Knust R, Ismael G, Rosenblatt E, Roth B, Villa L, Solares AL, Leon MX, Torres-Vigil I, Covarrubias-Gomez A, Hernández A, Bertolino M, Schwartsmann G, Santillana S, Esteva F, Fein L, Mano M, Gomez H, Hurlbert M, Durstine A, Azenha G
Jaar : 2013
Journal : Lancet Oncol
Volume : 14(5)
Pagina's : 391-436

Personalised cancer management: closer, but not here yet.

Auteurs : Piccart-Gebhart M
Jaar : 2013
Journal : Ann Oncol
Volume : 24(8)
Pagina's : 1951-5

Stem cell transplantation can provide durable disease control in Blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Auteurs : Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Iriondo Atienza A, Arcese W, Beelen DW, Cornelissen JJ, Kröger N, Milone G, Rossi G, Jardin F, Peters C, Rocha V, Sureda A, Mohty M, Dreger P
Jaar : 2013
Journal : Blood
Volume : 121(3)
Pagina's : 440-446

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Auteurs : Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M
Jaar : 2013
Journal : Breast
Volume : 22 Suppl 2
Pagina's : S152-5

Liquid-Based Cytology of the Breast: Pitfalls Unrecognized before Specific Liquid-Based Cytology Training - Proposal for a Modification of the Diagnostic Criteria.

Auteurs : Feoli F, Ameye L, Van Eeckhout P, Paesmans M, Marra V, Arisio R
Jaar : 2013
Journal : Acta Cytol.
Volume : 57(4)
Pagina's : 369-76

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Auteurs : Schöffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO
Jaar : 2013
Journal : Eur. J. Cancer
Volume : 49(15)
Pagina's : 3219-28

Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.

Auteurs : Saghatchian M, Mook S, Pruneri G, Viale G, Glas AM, Guerin S, Cardoso F, Piccart-Gebhart M, Tursz T, Delaloge S, van t Veer L
Jaar : 2013
Journal : Breast
Volume : 22(5)
Pagina's : 682-90

Distinct tumor protein p53 mutants in breast cancer subgroups.

Auteurs : Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, Plassa LF, Cottu P, Marty M, André F, Sotiriou C, Pusztai L, de Thé H
Jaar : 2013
Journal : Int. J. Cancer
Volume : 132(5)
Pagina's : 1227-31

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Auteurs : Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A
Jaar : 2013
Journal : Future Oncol
Volume : 9(10)
Pagina's : 1477-87

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.

Auteurs : Criscitiello C, Azim HA, Agbor-Tarh D, de Azambuja E, Piccart-Gebhart M, Baselga J, Eidtmann H, Di Cosimo S, Bradbury I, Rubio IT
Jaar : 2013
Journal : Ann Oncol
Volume : 24(8)
Pagina's : 1980-5

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Auteurs : Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart-Gebhart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS
Jaar : 2013
Journal : Adv Ther
Volume : 30(10)
Pagina's : 870-84

Thoracic oncology: annual review.

Auteurs : Sculier JP, Berghmans T, Meert AP
Jaar : 2013
Journal : Rev Med Brux
Volume : 34(2)
Pagina's : 100-11

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Auteurs : Goldhirsch A, Gelber Rd, Piccart-Gebhart M, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, Mcfadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J
Jaar : 2013
Journal : Lancet
Volume : 382(9897)
Pagina's : 1021-8